Alpenglow Biosciences, a pioneer in AI-powered 3D pathology, has announced a strategic, multi-year collaboration with Virdx, a biophysics AI company specializing in MRI-based cancer detection. The milestone-driven agreement aims to accelerate the development of next-generation diagnostic tools that integrate radiology and pathology, leveraging NVIDIA-accelerated computing to advance prostate cancer diagnostics. Virdx’s primary focus is to empower radiologists with non-invasive, dignified, and actionable methods for detecting prostate cancer. By combining Alpenglow’s whole-tissue 3D light-sheet microscopy (LSM) platform with Virdx’s AI-driven MRI analysis, the collaboration seeks to improve diagnostic accuracy by incorporating high-resolution 3D microscopic images that reveal architectural context, cellular details, and rare features invisible to conventional clinical imaging. The project will generate comprehensive 3D datasets using LSM to image full cross-sections of human prostate tissue—often exceeding 4 cm² in area. These datasets will serve as a high-resolution, ground-truth benchmark to validate and enhance the performance of Virdx’s MRI-based diagnostic models. “This agreement underscores the essential role of high-quality 3D pathology data in developing the next generation of AI-powered diagnostic tools,” said Nicholas Reder, MD, MPH, CEO and Co-Founder of Alpenglow Biosciences. “By combining our advanced imaging with Virdx’s AI expertise, we’re creating a powerful foundation for more accurate, early, and non-invasive cancer detection.” Jacob Murray, MD, CEO and Co-Founder of Virdx, added, “We’re excited to partner with Alpenglow. Their innovative technology and agile team are enabling us to generate the kind of high-fidelity, volumetric data that is critical for training our biophysics AI engine. This ground truth data will be instrumental in guiding our model development, with the ultimate goal of improving patient outcomes.” The collaboration highlights the growing importance of 3D pathology in bridging the gap between imaging and tissue analysis. By using NVIDIA GPUs on local infrastructure, both companies can process massive 3D microscopy datasets—each measuring several terabytes—up to 10 times faster than traditional CPU-based pipelines. This acceleration enables large-scale clinical validation and supports the development of AI models that can be deployed in real-world settings. Alpenglow Biosciences is a member of NVIDIA Inception, a global program supporting cutting-edge startups in AI and accelerated computing. Virdx develops biophysics AI models designed to unlock the full potential of magnetic resonance imaging, with an initial focus on prostate cancer. The company aims to enable imaging-based tissue characterization that supports non-invasive, actionable, and patient-centered diagnostics. Virdx collaborates with academic medical centers, radiology networks, and industry partners worldwide. Alpenglow Biosciences specializes in transforming biological tissue into rich, quantitative 3D data through AI-driven imaging and analysis. Its non-destructive platform digitizes entire tissue samples, delivering spatial insights at scale. By partnering with pharmaceutical and diagnostic leaders, Alpenglow is helping accelerate drug discovery, improve clinical diagnostics, and bring better treatments to patients faster.